I

ITCI

Intra-Cellular Therapies

This stock has been delisted.
News
Press Releases
Financial Reports
Profile
    Same Industry
    Name/Symbol
    Change%
    Price

    M

    McKesson

    MCK

    +1.37%
    884.28

    B

    Biogen Inc

    BIIB

    -3.50%
    177.34

    A

    Amgen Inc

    AMGN

    -1.51%
    347.94

    S

    Shire

    SHPG

    --
    179.20

    B

    Bristol-Myers Squibb Company Celegne Contingent Value Rights

    CELG-RT

    +34.65%
    0.1193

    L

    Lilly Eli & Co

    LLY

    -1.98%
    935.58

    C

    Celgene

    CELG

    --
    108.24

    T

    Therapeuticsmd Inc

    TXMD

    0.00%
    2.00

    J

    Johnson & Johnson

    JNJ

    -0.44%
    243.04

    A

    Abbvie Inc

    ABBV

    -2.86%
    208.84

    Z

    Zoetis Inc

    ZTS

    +0.55%
    117.94

    G

    Gilead Sciences Inc

    GILD

    -0.42%
    139.71

    N

    Novo-Nordisk A/S

    NVO

    +1.37%
    36.98

    B

    Bristol-Myers Squibb Co

    BMY

    -2.46%
    59.60

    A

    Alexion Pharms

    ALXN

    +1.70%
    182.50

    P

    Pfizer

    PFE

    -0.81%
    28.32

    S

    Sanofi FR

    SNY

    +0.34%
    47.89

    S

    Sanofi FR

    GCVRZ

    0.00%
    0.8711

    N

    Novartis

    NVS

    -0.68%
    154.03

    D

    Dr Reddys Labs

    RDY

    -1.11%
    13.32

    Contact Us

    Contact Number :+852 3852 8500
    Monday 7:00 AM - Saturday 9:00 AM (HKT)
    Service Email :service@webull.hk
    Online Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
    Business Cooperation :marketinghk@webull.hk
    Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
    Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
    Language

    English

    ©2026 Webull Securities Limited. All rights reserved.